graph Evidence gap map comparisons
anti-PD-(L)1pembrolizumab based treatment
pembrolizumab based treatment pembrolizumab alone
mHCC - 2nd line (L2) 2     
Comparator:  vs placebo; 
Risk of bias:  low;   some concerns;   high;  NA;